What Is Dextroamphetamine-Amphetamine? Uses and Risks

Dextroamphetamine-amphetamine is a prescription stimulant medication made up of a specific blend of amphetamine salts, most widely known by the brand name Adderall. The formulation contains roughly 75% dextroamphetamine and 25% levoamphetamine, split across four different salt forms. It is primarily prescribed for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, and it sits in the Schedule II controlled substance category due to its potential for misuse and dependence. How the drug actually works, what it does well, and what can go wrong with it are all worth understanding in more detail than a pharmacy leaflet typically provides.

What the Drug Actually Contains

The “mixed amphetamine salts” label is more literal than most people realize. Rather than a single chemical, the medication combines four amphetamine salts: amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. The net effect is a mixture that is about three-quarters dextroamphetamine and one-quarter levoamphetamine.¹ Dextroamphetamine is the more pharmacologically active isomer, meaning it has a stronger effect on the brain’s dopamine system. Levoamphetamine contributes more to peripheral stimulation, like effects on heart rate and blood pressure, though it has some central nervous system activity too.

The medication comes in both immediate-release (IR) tablets and extended-release (XR) capsules. The immediate-release version typically lasts about four to six hours and is sometimes dosed two or three times a day. The extended-release capsule uses a bead delivery system: half the beads dissolve right away, and the other half dissolve several hours later, stretching the effect across most of the day. Newer formulations continue to experiment with different delivery methods to fine-tune how quickly the drug kicks in and how long it lasts.²

How It Works in the Brain

Amphetamines increase the levels of certain chemical messengers in the brain, particularly dopamine and norepinephrine. The mechanism is not the same as drugs that simply block reuptake (the way some antidepressants work). Instead, amphetamine enters the nerve terminal, forces stored neurotransmitters out of their storage vesicles, and then reverses the direction of the transporters that normally pull dopamine and norepinephrine back into the cell. The result is that these neurotransmitters flood the space between neurons, amplifying their signaling.³ This boost in dopamine and norepinephrine is what improves focus and attention in people with ADHD, and it is also what produces the drug’s rewarding and potentially addictive properties.

Primary Uses

ADHD in Adults and Children

ADHD is by far the most common reason this drug is prescribed. A large Cochrane review that pooled data from 19 studies and over 2,500 adult participants found that amphetamines, including mixed amphetamine salts, produced meaningful reductions in ADHD symptom severity as rated by both clinicians and patients.⁴ The evidence quality was rated low to very low, which is common in psychiatric medication trials, but the direction of the effect was consistent across studies. In children, the drug has decades of clinical use supporting its effectiveness for reducing hyperactivity, impulsivity, and inattention.

Narcolepsy and Hypersomnia

Amphetamine-based stimulants have been used for narcolepsy since well before modern ADHD treatment existed. They promote wakefulness and help counteract the excessive daytime sleepiness that defines narcolepsy.⁵ In a randomized trial comparing amphetamine-dextroamphetamine to modafinil (another wakefulness-promoting drug) for idiopathic hypersomnia and narcolepsy type 2, the amphetamine formulation actually had a lower dropout rate due to side effects than modafinil, though appetite suppression was more common with amphetamine-dextroamphetamine.⁶ Despite their long-standing use in sleep disorders, there is still limited data on long-term cardiovascular risks and tolerance in narcolepsy patients specifically.

How It Compares to Methylphenidate

The other major class of ADHD stimulant is methylphenidate (brand names include Ritalin and Concerta). Parents and patients frequently want to know which one is “better,” and the honest answer is that they are close. Head-to-head studies in children have found that both drugs dramatically improve behavior, academic productivity, and parent and teacher ratings compared to placebo.⁷ Some of those studies found that the doses of Adderall tested appeared more potent than comparable doses of Ritalin, particularly in the afternoon when effects were wearing off, though this likely reflected dosing equivalence issues more than a true superiority of one drug class over the other.⁸ A retrospective analysis comparing the two found no statistically significant differences in efficacy or safety.⁹

In practice, individuals often respond better to one class than the other for reasons that remain poorly understood. It is common for a clinician to try one and switch to the other if the first does not work well or causes intolerable side effects. The choice between them often comes down to individual response, side effect profile, and practical considerations like how long the formulation lasts during the day.

Common Side Effects

The most frequently reported side effects are appetite suppression and insomnia, which show up across nearly every study regardless of age group. In a placebo-controlled trial in children, parents rated appetite problems, stomachaches, and trouble sleeping as worse during Adderall treatment compared to placebo.¹⁰ A crossover trial comparing dextroamphetamine and methylphenidate in children found that dextroamphetamine caused more severe insomnia, irritability, proneness to crying, anxiousness, and sadness than methylphenidate, though both drugs were well tolerated overall, with fewer than 2% of children on either drug discontinuing due to severe side effects.¹¹

Other commonly reported effects include dry mouth, headache, increased heart rate, jitteriness, and mood changes. Many of these side effects are dose-dependent, meaning they tend to be milder at lower doses and worse at higher ones. An interesting finding from that placebo-controlled trial: parents rated some “side effects” like staring, daydreaming, sadness, and irritability as actually worse during the placebo phase, suggesting some symptoms attributed to the medication are really features of untreated ADHD itself.¹⁰

Cardiovascular Concerns

Every stimulant medication carries warnings about cardiovascular effects. Amphetamines predictably raise heart rate and blood pressure to some degree, and these changes are well documented.¹² The question that worries most patients, though, is whether those changes translate into actual heart attacks, strokes, or dangerous arrhythmias. The picture here is more reassuring than the black-box warning might suggest, at least for people without pre-existing heart conditions. A study of older veterans comparing amphetamine-dextroamphetamine to methylphenidate found no difference in cardiovascular events between the two groups, with rates of about 4 to 5% over the study period.¹³ That said, rare events like arrhythmias and cardiomyopathy do occur, and less is known about those because they are hard to study in controlled trials. A baseline cardiovascular evaluation and periodic monitoring of blood pressure and heart rate are standard practice before and during treatment.

Psychiatric Risks at Higher Doses

One of the more serious risks of amphetamine-based medications is the potential to trigger psychosis or mania, particularly at higher doses. A case-control study found that people with past-month prescription amphetamine use had roughly 2.7 times the odds of psychosis or mania compared to non-users, and those taking higher doses (above 30 mg in dextroamphetamine equivalents) had over five times the odds.¹⁴ A separate large study looking across all ADHD medications (including methylphenidate and atomoxetine, not just amphetamines) estimated the overall risk of hospitalization for first-onset psychosis or mania at about 1 in 264 treated adults.¹⁵

These numbers are small in absolute terms, but the dose-response relationship is worth paying attention to. The risk climbs as the dose goes up, which is one reason clinicians generally start at the lowest effective dose and increase cautiously. People with a personal or family history of psychotic disorders or bipolar disorder are at higher risk and need especially careful monitoring.

Effects on Growth in Children

Growth suppression is one of the most consistent findings in pediatric stimulant research. Children on extended-release mixed amphetamine salts have been shown to grow less than expected in both height and weight, with the largest deficits occurring during the first year of treatment. After that first year, the rate of growth loss slows considerably and is generally not significant in the second year.¹⁶ The deficits tend to be greatest in children who are already heavier or taller before treatment. A review of stimulant effects on growth noted that the rate of height loss appears relatively small and is likely reversible if the medication is stopped, though long-term follow-up on final adult height is limited.¹⁷ Periodic height and weight monitoring is recommended for any child on stimulant treatment.¹⁸

Pregnancy and Breastfeeding

This is an area where many people expect clear danger signals, but the data is more nuanced. A large study examining the link between stimulant use in pregnancy and birth defects found a small increase in the risk of cardiac malformations associated with methylphenidate exposure, but not with amphetamine exposure.¹⁹ A separate study looking at birth weight found no significant difference between infants exposed to amphetamine-dextroamphetamine in utero and those who were not, though the sample size was limited.²⁰ Despite these somewhat reassuring findings, most clinical guidelines still recommend weighing the risks and benefits carefully with a physician, since controlled data in pregnant populations is inherently limited and the drug does cross the placenta.

Tolerance, Dependence, and Withdrawal

Tolerance to amphetamines does develop, though it is not quite the simple “the drug stops working” story that many people imagine. Research suggests that tolerance involves a shift in the baseline state rather than a straightforward loss of drug potency. In animal studies, withdrawal-related cues after even a single dose of amphetamine lasted roughly three times longer than the effects of the drug itself.²¹ In people who take the medication daily for long periods, stopping abruptly can produce a recognizable withdrawal pattern. The initial “crash” phase starts as the drug wears off and can include fatigue, flat mood, increased sleep, and sometimes severe depressive symptoms. A withdrawal phase follows a few days later and can bring strong cravings, fluctuating energy, irritability, insomnia or excessive sleep, poor concentration, and anxiety. These symptoms usually resolve over weeks, though the timeline varies.²²

Physical dependence and withdrawal are not the same as addiction. Many patients take this medication for years as prescribed without developing addictive patterns. The risk of addiction is higher in people who take the drug at higher-than-prescribed doses, take it by non-oral routes (snorting or injecting), or have a history of substance use disorders.

Misuse Outside of Prescriptions

Prescription stimulant misuse is particularly common on college campuses. Estimates suggest that up to 20% of college students have used prescription stimulants that were not prescribed to them.²³ The motivations are revealing: in a survey at one academic health sciences center, about two-thirds of those who misused stimulants said they did so for alertness or energy, and over half cited academic performance. Only about 5% used them to get high.²⁴ The perception that these are harmless “study drugs” is widespread but misleading. Taking amphetamines without medical supervision means no dosing oversight, no screening for cardiovascular or psychiatric risk factors, and no monitoring for side effects. The dose-dependent risk of psychosis described earlier does not care whether the pill came from a prescription or a friend’s bottle.

What Happens in an Overdose

Amphetamine overdose produces an exaggerated version of the drug’s normal effects. The body’s “fight or flight” system goes into overdrive. Symptoms can include rapid heart rate, high blood pressure, dangerously elevated body temperature, tremors, agitation, hallucinations, paranoia, seizures, and in severe cases, cardiovascular collapse.²⁵ There is no specific antidote. Treatment focuses on managing the most dangerous symptoms: benzodiazepines for seizures and agitation, beta-blockers or other agents for dangerously fast heart rhythms, and intravenous fluids to manage body temperature and support kidney function.²⁶ If someone taking this medication or anyone around them shows signs of overdose, emergency medical attention is critical.

Athletic Performance and Stimulant Bans

Amphetamines are banned by virtually every major sports governing body, and there is evidence to support why. A systematic review and meta-analysis of stimulant medications and athletic performance found that the majority of included studies showed significant improvements in physical performance with stimulant use. Both methylphenidate and amphetamine were consistently linked to performance-enhancing effects, along with increases in heart rate, core body temperature, and various stress hormone levels.²⁷ Athletes with legitimate ADHD diagnoses can sometimes obtain therapeutic use exemptions, but the process is intentionally rigorous. The combination of performance enhancement and cardiovascular strain makes unsupervised use during intense physical activity especially risky.

Long-Term Effects on Brain Structure

Whether years of stimulant use change the brain structurally is an active area of research with results pointing in two different directions. One study in children found that greater cumulative exposure to ADHD medication, including dextroamphetamine formulations, was associated with smaller volumes in certain subregions of the hippocampus, a brain area involved in memory.²⁸ On the other hand, a longitudinal study in adults tracked ADHD patients over three years and found that those who took stimulant medication actually showed more normal brain volumes in a region called the putamen compared to untreated patients, whose putamen volumes decreased over time. The medicated group’s brain volumes looked similar to healthy controls, suggesting the medication may help normalize certain structural differences associated with ADHD rather than cause harm.²⁹

These findings are not contradictory so much as incomplete. Different brain regions, different age groups, and different durations of treatment may tell different stories. The research on this front is still young, and no study yet has followed a large group of medicated people from childhood through adulthood with repeated brain imaging. For now, the clinical consensus remains that the known benefits of treating ADHD outweigh the uncertain and small structural changes observed so far, but it is an area that deserves continued attention from researchers.